Advertisement

Topics

Korea's ViroMed Starts Trial of Gene Therapy for Diabetic Foot Ulcers

23:28 EDT 4 Aug 2017 | ChinaBio Today

ViroMed of South Korea has begun dosing patients in a US Phase III trial of VM202, a gene therapy drug, in patients with non-healing diabetic foot ulcers and concomitant peripheral artery disease. Earlier this year, ViroMed filed in China to start a Phase III trial of VM202 in patients with critical limb ischemia, an advanced state of peripheral artery disease. When injected into muscles, VM202 is intended to induce new microvasculature and alleviate a number of conditions associated with diabetes and loss of peripheral arteries. More details....

Stock Symbol: (KOSDAQ: 084990)

Share this with colleagues:  

Original Article: Korea's ViroMed Starts Trial of Gene Therapy for Diabetic Foot Ulcers

NEXT ARTICLE

More From BioPortfolio on "Korea's ViroMed Starts Trial of Gene Therapy for Diabetic Foot Ulcers"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...